Scott A. Browne

Array ( [id] => 15147893 [patent_doc_number] => 20190352424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => ERBB2 SIGNALING AND NERVE REGENERATION [patent_app_type] => utility [patent_app_number] => 16/431082 [patent_app_country] => US [patent_app_date] => 2019-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16431082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14868121 [patent_doc_number] => 20190284302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => Human Anti-SOD1 Antibodies [patent_app_type] => utility [patent_app_number] => 16/424169 [patent_app_country] => US [patent_app_date] => 2019-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16424169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15117211 [patent_doc_number] => 20190345238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/419527 [patent_app_country] => US [patent_app_date] => 2019-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20941 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16419527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17000588 [patent_doc_number] => 11079392 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Methods and compositions for detecting misfolded proteins [patent_app_type] => utility [patent_app_number] => 16/406942 [patent_app_country] => US [patent_app_date] => 2019-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 72 [patent_no_of_words] => 32338 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16406942 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14932977 [patent_doc_number] => 20190302126 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => FARBER DISEASE MARKERS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/362102 [patent_app_country] => US [patent_app_date] => 2019-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21424 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16362102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16742028 [patent_doc_number] => 10966997 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-06 [patent_title] => Methods for treating degenerative disc disease and chronic lower back pain [patent_app_type] => utility [patent_app_number] => 16/354318 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 9263 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16354318 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14566967 [patent_doc_number] => 20190211090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => METHOD OF TREATING OSTEOARTHRITIS WITH AN ANTIBODY TO NGF [patent_app_type] => utility [patent_app_number] => 16/282120 [patent_app_country] => US [patent_app_date] => 2019-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16282120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16830946 [patent_doc_number] => 11007176 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Use of actin depolymerizing agents for the treatment of anxiety disorders [patent_app_type] => utility [patent_app_number] => 16/279366 [patent_app_country] => US [patent_app_date] => 2019-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 9646 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16279366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14566983 [patent_doc_number] => 20190211098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => USE OF PILRA BINDING AGENTS FOR TREATMENT OF A DISEASE [patent_app_type] => utility [patent_app_number] => 16/227923 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34680 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16227923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14213913 [patent_doc_number] => 20190119341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => Compositions of phosphorylated tau peptides and uses thereof [patent_app_type] => utility [patent_app_number] => 16/169215 [patent_app_country] => US [patent_app_date] => 2018-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22930 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16169215 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16550828 [patent_doc_number] => 10883982 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-05 [patent_title] => Methods for determining molecule folding associated with proteopathies [patent_app_type] => utility [patent_app_number] => 16/158074 [patent_app_country] => US [patent_app_date] => 2018-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 30 [patent_no_of_words] => 13464 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16158074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16060989 [patent_doc_number] => 10689426 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-23 [patent_title] => Artificial synapse inducer and method of making the same [patent_app_type] => utility [patent_app_number] => 16/155209 [patent_app_country] => US [patent_app_date] => 2018-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 9633 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16155209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15724303 [patent_doc_number] => 10610566 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-04-07 [patent_title] => Inducing CNS neurite outgrowth with [patent_app_type] => utility [patent_app_number] => 16/144208 [patent_app_country] => US [patent_app_date] => 2018-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 28 [patent_no_of_words] => 13809 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16144208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14578583 [patent_doc_number] => 20190216900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => METHODS OF TREATING MILD BRAIN INJURY [patent_app_type] => utility [patent_app_number] => 16/143735 [patent_app_country] => US [patent_app_date] => 2018-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22538 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16143735 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13793367 [patent_doc_number] => 20190010222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => STABILIZED FORMULATIONS CONTAINING ANTI-NGF ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/135953 [patent_app_country] => US [patent_app_date] => 2018-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14092 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16135953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836249 [patent_doc_number] => 20190276525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/129674 [patent_app_country] => US [patent_app_date] => 2018-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16129674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14213909 [patent_doc_number] => 20190119339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => NOVEL HUMAN ULIP/CRMP PROTEIN AND USE THEREOF IN DIAGNOSIS AND TREATMENT OF CANCERS AND PARANEOPLASTIC NEUROLOGICAL SYNDROMES [patent_app_type] => utility [patent_app_number] => 16/129279 [patent_app_country] => US [patent_app_date] => 2018-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5602 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16129279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14016507 [patent_doc_number] => 20190070247 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => Compositions and Methods for Treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA) and Other Neurodegenerative Disorders Associated with Aberrant Amyloid Deposits [patent_app_type] => utility [patent_app_number] => 16/124798 [patent_app_country] => US [patent_app_date] => 2018-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12404 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16124798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622155 [patent_doc_number] => 20180362629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => ANTI-NGF ANTIBODIES AND THEIR USE [patent_app_type] => utility [patent_app_number] => 16/118757 [patent_app_country] => US [patent_app_date] => 2018-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52971 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16118757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238258 [patent_doc_number] => 20200255492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => LEPTIN PEPTIDES AND THEIR USE FOR TREATING NEUROLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 16/642627 [patent_app_country] => US [patent_app_date] => 2018-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16642627 [rel_patent_id] =>[rel_patent_doc_number] =>)